Ocular Therapeutix:Axpaxli针对湿性年龄相关性黄斑变性的补充性Sol-R三期非劣效性试验将按计划进行,顶线数据预计于2027年第一季度公布

美股速递
Feb 17

Ocular Therapeutix宣布,其候选药物Axpaxli用于治疗湿性年龄相关性黄斑变性的补充性Sol-R三期非劣效性试验,将依照原定方案继续推进。该试验的顶线数据结果预计将在2027年第一季度揭晓。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10